U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula CO3.Ca
Molecular Weight 100.087
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CALCIUM CARBONATE

SMILES

[Ca++].[O-]C([O-])=O

InChI

InChIKey=VTYYLEPIZMXCLO-UHFFFAOYSA-L
InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.alfa.com/en/catalog/043674/

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Originator

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
511
Unknown

Approved Use

Unknown
Palliative
Phase I
438
Unknown

Approved Use

Unknown
Palliative
Phase I
438
Unknown

Approved Use

Unknown
Primary
Approved
8583
Unknown

Approved Use

Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred
PubMed

PubMed

TitleDatePubMed
Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension?
1999 Jul 30
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein.
1999 Nov
Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes.
1999 Sep
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.
1999 Sep
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.
1999 Sep 20
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells.
2000 Aug
Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density.
2000 Aug
Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes.
2000 Dec
Inactivation properties of human recombinant class E calcium channels.
2000 Feb
Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V.
2000 Feb 11
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.
2000 Feb 15
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation.
2000 Jan 15
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
2000 Jan 7
A family of gamma-like calcium channel subunits.
2000 Mar 24
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.
2000 Oct 15
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension.
2000 Sep
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake.
2000 Sep
Ca2+-induced contraction of cat esophageal circular smooth muscle cells.
2001 Apr
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations.
2001 Apr 7
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells.
2001 Aug
Complement activation in factor D-deficient mice.
2001 Dec 4
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine.
2001 Jul
Analysis of the native quaternary structure of vanilloid receptor 1.
2001 Jul 27
Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B.
2001 Jun
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.
2001 Jun
Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D.
2001 Jun
[Acute renal failure caused by hypercalcemia].
2001 Jun 10
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.
2001 Jun 8
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.
2001 Oct 26
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.
2001 Sep
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore.
2001 Sep 1
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats.
2002
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells.
2002 Apr 19
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.
2002 Dec
Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones.
2002 Jul
Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.
2002 Jul
Human kidney diamine oxidase: heterologous expression, purification, and characterization.
2002 Jun
Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors.
2002 Sep 15
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension.
2003 Jan
Patents

Patents

03966773
135
03974176
92
03981818
90
04008309
67
04028407
65
04041173
65
04042702
90
04058507
65
04063023
65
06485737
65
06497902
65
08637538
65
20090030026
65
20130174651
65
JP2017071731
65
US2143359
65

Sample Use Guides

In Vivo Use Guide
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
HYDROLYZED PEARL
INCI  
INCI  
Preferred Name English
CALCITE
INCI  
Preferred Name English
CHALK
INCI   WHO-DD  
INCI  
Preferred Name English
CI 77220
INCI  
INCI  
Preferred Name English
CALCIUM CARBONATE
EP   FCC   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
INS-170(I)
Code English
MARBLE DUST
Common Name English
CALCII CARBONAS [WHO-IP LATIN]
Common Name English
GLAUBERITUM
Common Name English
PRECPITATED CALCIUM CARBONATE [JAN]
Common Name English
LIMESTONE, GROUND
FCC  
Common Name English
Calcium carbonate (1:1)
Systematic Name English
CALCIUM CARBONATE [HSDB]
Common Name English
CALCIUM (AS CARBONATE)
Common Name English
CALCIUM CARBONATE [FCC]
Common Name English
CALCIUM CARBONATE DC (SPRAY DRIED) [NDI]
Common Name English
NDI 443 [FDMS]
Code English
PEPCID COMPLETE COMPONENT CALCIUM CARBONATE
Common Name English
LIMESTONE, GROUND [FCC]
Common Name English
Chalk [WHO-DD]
Common Name English
CALCIUM CARBONATE [EP MONOGRAPH]
Common Name English
CALCIUM CARBONATE [WHO-IP]
Common Name English
HAN SHUI SHI
Common Name English
CALCITE (CA(CO3))
Common Name English
CALCIUM CARBONATE [MI]
Common Name English
CALCIUM CARBONATE [MART.]
Common Name English
E-170(I)
Code English
INS NO.170(I)
Code English
PHX CAL-CARB BUFFER
Brand Name English
CALCIUM (AS CALCIUM CARBONATE)
VANDF  
Common Name English
CALCIUM CARBONATE [USP-RS]
Common Name English
CALCIUM CARBONATE [USP MONOGRAPH]
Common Name English
CALCIUM CARBONATE [ORANGE BOOK]
Common Name English
CALCIUM (AS CALCIUM CARBONATE) [VANDF]
Common Name English
CALCIUM (AS CARBONATE) [VANDF]
Common Name English
LIMESTONE
Common Name English
CALCIUM CARBONATE [VANDF]
Common Name English
CALCITUM
Common Name English
PRECPITATED CALCIUM CARBONATE
JAN  
Common Name English
CALCIUM CARBONATE [II]
Common Name English
Calcium carbonate [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QA12AA04
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
EPA PESTICIDE CODE 73502
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
WHO-ATC A12AA04
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
CFR 21 CFR 178.3297
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
CFR 21 CFR 331.11
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
CFR 21 CFR 184.1191
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
JECFA EVALUATION INS-170(I)
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
LOINC 32156-2
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
WHO-VATC QA02AC01
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
CFR 21 CFR 176.170
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
CFR 21 CFR 331.15
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
CODEX ALIMENTARIUS (GSFA) INS-170(I)
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
FDA ORPHAN DRUG 42189
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
CFR 21 CFR 184.1409
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
WHO-ATC A02AC01
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
Code System Code Type Description
DRUG BANK
DB06724
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
CONCEPT Dietary Supplement
MESH
D002119
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CALCIUM CARBONATE
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY Description: A white, fine, microcrystalline powder; odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS. It dissolves with effervescence in acetic acid (~60 g/l) TS, hydrochloric acid (~70 g/l) TS, and nitric acid (~130 g/l) TS. Category: Antacid. Storage: Calcium carbonate should be kept in a well-closed container. Definition: Calcium carbonate contains not less than 98.0% and not more than 100.5% of CaCO3, calculated with reference to the dried substance.
EVMPD
SUB13166MIG
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
CAS
13397-26-7
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
ALTERNATIVE
ECHA (EC/EINECS)
207-439-9
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
CAS
1317-65-3
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
ALTERNATIVE
DAILYMED
H0G9379FGK
Created by admin on Mon Mar 31 18:23:00 GMT 2025 , Edited by admin on Mon Mar 31 18:23:00 GMT 2025
PRIMARY
WIKIPEDIA
CALCIUM CARBONATE
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
PUBCHEM
10112
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
CHEBI
46719
Created by admin on Mon Mar 31 18:23:00 GMT 2025 , Edited by admin on Mon Mar 31 18:23:00 GMT 2025
PRIMARY
CHEBI
31344
Created by admin on Mon Mar 31 18:23:00 GMT 2025 , Edited by admin on Mon Mar 31 18:23:00 GMT 2025
PRIMARY
CAS
471-34-1
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
FDA UNII
H0G9379FGK
Created by admin on Mon Mar 31 18:23:00 GMT 2025 , Edited by admin on Mon Mar 31 18:23:00 GMT 2025
PRIMARY
CAS
287389-46-2
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
ALTERNATIVE
CHEBI
3311
Created by admin on Mon Mar 31 18:23:00 GMT 2025 , Edited by admin on Mon Mar 31 18:23:00 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-279-6
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
ALTERNATIVE
ChEMBL
CHEMBL1200539
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
RXCUI
1897
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
NCI_THESAURUS
C332
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
EPA CompTox
DTXSID3036238
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
HSDB
927
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
RS_ITEM_NUM
1086403
Created by admin on Mon Mar 31 18:23:00 GMT 2025 , Edited by admin on Mon Mar 31 18:23:00 GMT 2025
PRIMARY
MERCK INDEX
m2929
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY Merck Index
DRUG CENTRAL
4239
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
PRIMARY
SMS_ID
100000091518
Created by admin on Mon Mar 31 18:23:00 GMT 2025 , Edited by admin on Mon Mar 31 18:23:00 GMT 2025
PRIMARY
RXCUI
349908
Created by admin on Mon Mar 31 18:22:59 GMT 2025 , Edited by admin on Mon Mar 31 18:22:59 GMT 2025
ALTERNATIVE
ACTIVE MOIETY
Structure of CALCIUM CATION
ACTIVE MOIETY
Structure of CARBONATE ION
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966